-72%

est. 2Y upside i

DevOps & InfraAI & ML

Interfere’s mission is to build the “self-healing layer of the internet”: software that detects bugs, figures out a root cause, and ships its own fix – all before a human can open logs. Unlike traditional observability tools that aim to make logs easier to read, Interfere will eliminate the need to read logs at all.

Rank

#1879

Sector

Developer Tools, AI Software

Est. Liquidity

~6Y

Data Quality

Data: Low

Interfere is a very early-stage (Seed round) company with a compelling, disruptive vision in the AI-driven observability space, aiming to replace legacy tools.

Last updated: February 25, 2026

Bull (9%)+400%

Interfere successfully develops its proprietary AI/ML technology, achieving significant market traction by demonstrating clear ROI in reducing developer time spent on bug fixing. It captures a niche in the enterprise market, leading to rapid revenue growth and an acquisition by a major cloud provider or a successful Series B/C round at a $125M valuation, representing a 5x return on the current valuation.

Base (50%)+100%

Interfere gains initial traction with early adopters and small to mid-sized companies, proving its core value proposition. However, competition from incumbents and other AI observability startups limits its market share expansion. It achieves modest growth, leading to a Series B round or a small acquisition at a $50M valuation, doubling the current equity value.

Bear (41%)-80%

Dominant observability incumbents (e.g., Datadog, Dynatrace) rapidly integrate similar AI-driven self-healing capabilities, or a well-funded competitor emerges, commoditizing Interfere's offering. The company struggles to find product-market fit at scale, leading to a down round or failure to raise further capital, resulting in a liquidation event at a $5M valuation, wiping out most common stock value.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

With $4.94M raised on an estimated $25M post-money valuation, investors hold approximately 19.8% of the company's value in liquidation preferences.

Dilution Risk

high

As a Seed stage company, Interfere will require multiple future funding rounds, leading to significant dilution for early common stock holders.

Secondary Liquidity

none

Given its very early Seed stage, there is no active secondary market or tender offers for Interfere's equity.

View all 6 open roles at Interfere →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Interfere's data — designed to show you've done your homework.

  • 1

    “Given the strong presence of incumbents like Datadog and Dynatrace in the observability space, how does Interfere plan to differentiate its 'self-healing layer' beyond initial feature sets to build a sustainable competitive moat?”

  • 2

    “With a Seed round completed in late 2025, what are the key milestones and metrics (e.g., ARR targets, customer acquisition costs, retention rates) the company is focused on achieving in the next 12-18 months to secure a successful Series A?”

  • 3

    “Considering the 'high' incumbent threat and the challenges of developer tool monetization, what is Interfere's strategy for pricing and go-to-market to ensure enterprise adoption and robust revenue growth, rather than just individual developer usage?”

Community

Valuation Sentiment

Our model estimates -72% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.